Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)

समान संसाधन

• Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
  द्वारा: Nishii, Kazuya, और अन्य
  प्रकाशित: (2021)
• Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
  द्वारा: White, Maya N, और अन्य
  प्रकाशित: (2021)
• Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor‐mutated lung cancer model
  द्वारा: Hayakawa, Hiromi, और अन्य
  प्रकाशित: (2013)
• First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
  द्वारा: Ricciuti, Biagio, और अन्य
  प्रकाशित: (2018)
• Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
  द्वारा: Makimoto, Go, और अन्य
  प्रकाशित: (2019)